Login Register Cart 0
Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Efficacy of Direct-Acting Antiviral Combination Therapy in the Treatment of Hepatitis C Virus Among Kidney Transplant Patients

Author(s): Mohammed Al Atbee, Saad Shaheen Al-Taher and Majid Alabbood*

Volume 19, Issue 2, 2021

Published on: 03 July, 2020

Page: [169 - 173] Pages: 5

DOI: 10.2174/2211352518999200703114432

Price: $65

Abstract

Background: To date, there is no consensus on the best combination of direct-acting antivirals to treat hepatitis C virus in kidney transplant recipients.

Objective: This study aims to analyze the efficacy of a combination of sofosbuvir and ledipasvir regimen for the treatment of hepatitis C virus infected kidney transplant patients.

Methods: A cross-sectional study was conducted in a nephrology clinic and the Nephrology Center in Basrah Teaching Hospital from June 2015 to June 2018. Ledifos (90 mg Ledipasvir and 400 mg Sofosbuvir fixed-dose) was given as a single daily dose to all the participants for 12 weeks. Response for therapy was tested by a follow up hepatitis C virus load at the end of 12 weeks and after 24 weeks. The sustained virological response was defined as a negative viral load of hepatitis C virus (aviremia) at the end of therapy. This study was done according to the Helsinki Congress.

Results: A total of 60 (16 females) patients with renal transplantation and hepatitis C virus infection were included. The mean age was 40±6.2 years. A sustained virological response was observed in all of the patients who received Ledifos after 12 and 24 weeks of therapy for all genotypes (1a, 1b and 4); p= 0.0001. Genotype 1a was more prevalent among males, in about 34 (56.6%) of the patients; p= 0.0001, and it was the most common genotype that tested negative serologically, 11 (18.3%).

Conclusion: Ledifos therapy is an effective and safe option for the treatment of hepatitis C virus infection in the post-renal transplant setting.

Keywords: Hepatitis C virus, kidney transplant, direct antiviral drug, genotype, ledipasvir, sofosbuvir, sustained virological response.

Graphical Abstract

[1]
Carpio, R.; Pamugas, G.E.; Danguilan, R.; Que, E. Outcomes of renal allograft recipients with hepatitis C. Transplant. Proc., 2016, 48(3), 836-839.
[http://dx.doi.org/10.1016/j.transproceed.2016.02.050] [PMID: 27234747]
[2]
Fabrizi, F.; Martin, P.; Dixit, V.; Messa, P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J. Viral Hepat., 2014, 21(5), 314-324.
[http://dx.doi.org/10.1111/jvh.12148] [PMID: 24716634]
[3]
Morales, J.M.; Fabrizi, F. Hepatitis C and its impact on renal transplantation. Nat. Rev. Nephrol., 2015, 11(3), 172-182.
[http://dx.doi.org/10.1038/nrneph.2015.5] [PMID: 25643666]
[4]
Rostami, Z.; Nourbala, M.H.; Alavian, S.M.; Bieraghdar, F.; Jahani, Y.; Einollahi, B. The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepat. Mon., 2011, 11(4), 247-254.
[PMID: 22087151]
[5]
Bloom, R.D.; Lake, J.R. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am. J. Transplant., 2006, 6(10), 2232-2237.
[http://dx.doi.org/10.1111/j.1600-6143.2006.01457.x] [PMID: 16869798]
[6]
Gürsoy, M.; Güvener, N.; Köksal, R.; Karavelioğlu, D.; Baysal, C.; Ozdemir, N.; Boyacioğlu, S.; Bilgin, N.; Erdal, R. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant. Proc., 2000, 32(3), 561-562.
[http://dx.doi.org/10.1016/S0041-1345(00)00890-3] [PMID: 10812113]
[7]
Morales, J.M.; Domínguez-Gil, B.; Sanz-Guajardo, D.; Fernández, J.; Escuin, F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol. Dial. Transplant., 2004, 19(3)(Suppl. 3), iii72-iii76.
[http://dx.doi.org/10.1093/ndt/gfh1020] [PMID: 15192141]
[8]
Bouthot, B.A.; Murthy, B.V.; Schmid, C.H.; Levey, A.S.; Pereira, B.J. Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for policies on organ procurement. Transplantation, 1997, 63(6), 849-853.
[http://dx.doi.org/10.1097/00007890-199703270-00010] [PMID: 9089225]
[9]
Fabrizi, F.; Verdesca, S.; Messa, P.; Martin, P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig. Dis. Sci., 2015, 60(12), 3801-3813.
[http://dx.doi.org/10.1007/s10620-015-3801-y] [PMID: 26195311]
[10]
Ladino, M.; Pedraza, F.; Roth, D. Hepatitis C virus infection in chronic kidney disease. J. Am. Soc. Nephrol., 2016, 27(8), 2238-2246.
[http://dx.doi.org/10.1681/ASN.2016010030] [PMID: 27095799]
[11]
Jensen, D.; O’Leary, J.; Pockros, P.; Sherman, K.; Kwo, P.; Mailliard, M. Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort: 45; Hepatol, 2014, p. 60.
[12]
Bukh, J.; Wantzin, P.; Krogsgaard, K.; Knudsen, F.; Purcell, R.H.; Miller, R.H. Copenhagen Dialysis HCV Study Group. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J. Infect. Dis., 1993, 168(6), 1343-1348.
[http://dx.doi.org/10.1093/infdis/168.6.1343] [PMID: 7504031]
[13]
Pawlotsky, J.M. Use and interpretation of virological tests for hepatitis C. Hepatology, 2002, 36(5)(Suppl. 1), S65-S73.
[PMID: 12407578]
[14]
Thio, C.L.; Nolt, K.R.; Astemborski, J.; Vlahov, D.; Nelson, K.E.; Thomas, D.L. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J. Clin. Microbiol., 2000, 38(2), 575-577.
[http://dx.doi.org/10.1128/JCM.38.2.575-577.2000] [PMID: 10655348]
[15]
Beiras-Fernandez, A.; Thein, E.; Hammer, C. Induction of immunosuppression with polyclonal antithymocyte globulins: an overview. Exp. Clin. Transplant., 2003, 1(2), 79-84.
[PMID: 15859913]
[16]
Gabardi, S.; Martin, S.T.; Roberts, K.L.; Grafals, M. Induction immunosuppressive therapies in renal transplantation. Am. J. Health Syst. Pharm., 2011, 68(3), 211-218.
[http://dx.doi.org/10.2146/ajhp090636] [PMID: 21258026]
[17]
Afdhal, N.; Reddy, K.R.; Nelson, D.R.; Lawitz, E.; Gordon, S.C.; Schiff, E.; Nahass, R.; Ghalib, R.; Gitlin, N.; Herring, R.; Lalezari, J.; Younes, Z.H.; Pockros, P.J.; Di Bisceglie, A.M.; Arora, S.; Subramanian, G.M.; Zhu, Y.; Dvory-Sobol, H.; Yang, J.C.; Pang, P.S.; Symonds, W.T.; McHutchison, J.G.; Muir, A.J.; Sulkowski, M.; Kwo, P. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med., 2014, 370(16), 1483-1493.
[http://dx.doi.org/10.1056/NEJMoa1316366] [PMID: 24725238]
[18]
Kowdley, K.V.; Gordon, S.C.; Reddy, K.R.; Rossaro, L.; Bernstein, D.E.; Lawitz, E.; Shiffman, M.L.; Schiff, E.; Ghalib, R.; Ryan, M.; Rustgi, V.; Chojkier, M.; Herring, R.; Di Bisceglie, A.M.; Pockros, P.J.; Subramanian, G.M.; An, D.; Svarovskaia, E.; Hyland, R.H.; Pang, P.S.; Symonds, W.T.; McHutchison, J.G.; Muir, A.J.; Pound, D.; Fried, M.W. ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med., 2014, 370(20), 1879-1888.
[http://dx.doi.org/10.1056/NEJMoa1402355] [PMID: 24720702]
[19]
Chen, K.; Lu, P.; Song, R.; Zhang, J.; Tao, R.; Wang, Z.; Zhang, W.; Gu, M. Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study. Medicine (Baltimore), 2017, 96(30)e7568
[http://dx.doi.org/10.1097/MD.0000000000007568] [PMID: 28746204]
[20]
Kamar, N.; Marion, O.; Rostaing, L.; Cointault, O.; Ribes, D.; Lavayssière, L.; Esposito, L.; Del Bello, A.; Métivier, S.; Barange, K.; Izopet, J.; Alric, L. Efficacy and safety of sofosbuvir‐based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am. J. Transplant., 2016, 16(5), 1474-1479.
[http://dx.doi.org/10.1111/ajt.13518] [PMID: 26587971]
[21]
Reddy, K.; Sulkowski, M.; Hassan, M.; Levitsky, J.; O’Leary, J.; Brown, R. Safety and efficacy of new DAA regimens in kidney and liver transplant recipients with hepatitis C: interval results from the HCV-target study. J. Hepatol., 2016, 64(2), 783-784.
[http://dx.doi.org/10.1016/S0168-8278(16)01529-4]
[22]
Sawinski, D.; Kaur, N.; Ajeti, A.; Trofe-Clark, J.; Lim, M.; Bleicher, M.; Goral, S.; Forde, K.A.; Bloom, R.D. Successful treatment of hepatitis C in renal transplant recipients with direct‐acting antiviral agents. Am. J. Transplant., 2016, 16(5), 1588-1595.
[http://dx.doi.org/10.1111/ajt.13620] [PMID: 26604182]

Rights & Permissions Print Cite
Article Metrics
8
1
© 2024 Bentham Science Publishers | Privacy Policy